These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Kypreos KE; Bitzur R; Karavia EA; Xepapadaki E; Panayiotakopoulos G; Constantinou C Angiology; 2019 Mar; 70(3):197-209. PubMed ID: 29862840 [TBL] [Abstract][Full Text] [Related]
8. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Hersberger M; von Eckardstein A Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163 [TBL] [Abstract][Full Text] [Related]
9. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J; Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972 [TBL] [Abstract][Full Text] [Related]
10. Optimal therapy of low levels of high density lipoprotein-cholesterol. Kashyap ML; Tavintharan S; Kamanna VS Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946 [TBL] [Abstract][Full Text] [Related]
11. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Feig JE; Shamir R; Fisher EA Curr Drug Targets; 2008 Mar; 9(3):196-203. PubMed ID: 18336237 [TBL] [Abstract][Full Text] [Related]
12. Role of HDL in those with diabetes. Santos-Gallego CG; Rosenson RS Curr Cardiol Rep; 2014 Sep; 16(9):512. PubMed ID: 25199216 [TBL] [Abstract][Full Text] [Related]
13. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
14. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? Page MM; Hooper AJ; Burnett JR Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232 [TBL] [Abstract][Full Text] [Related]
15. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300 [TBL] [Abstract][Full Text] [Related]